GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel


This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.

Full Title of Study: “Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection in Healthcare Personnel”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: September 2020

Detailed Description

This Phase II randomized, placebo-controlled, double-blind study will assess whether topical GLS-1200 applied via nasal spray atomizer is well-tolerated and can reduce the incidence of confirmed SARS-CoV-2 infection. Subjects will be randomized to either the GLS-1200 or placebo group in a 2:1 ratio with a target enrollment of 225 subjects. Subjects will self-administer study drug three times daily for 4 weeks.


  • Drug: GLS-1200
    • GLS-1200 is given as a nasal spray using an atomizer
  • Drug: Placebo
    • Placebo is given as a nasal spray using an atomizer

Arms, Groups and Cohorts

  • Experimental: GLS-1200
    • 1 mL of GLS-1200 per nostril, TID
  • Placebo Comparator: 0.9 %Saline
    • 1 mL of 0.9% Saline per nostril, TID

Clinical Trial Outcome Measures

Primary Measures

  • Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0
    • Time Frame: 4 weeks of treatment
  • Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group
    • Time Frame: 4 weeks of treatment

Secondary Measures

  • Symptom score of documented SARS-CoV-2 infection relative to treatment group with a higher score being a worse outcome.
    • Time Frame: 4 weeks of treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18 or older
  • Able to provide informed consent
  • Able and willing to comply with study procedures
  • Adult healthcare professional

Exclusion Criteria

  • Know allergy to quinine, quinidine, or mefloquine
  • Confirmed prior positive test for SARS-CoV-2
  • Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • GeneOne Life Science, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Medical Monitor, 484-965-9147,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.